Search

Your search keyword '"Ribaudo, Heather J"' showing total 466 results

Search Constraints

Start Over You searched for: Author "Ribaudo, Heather J" Remove constraint Author: "Ribaudo, Heather J"
466 results on '"Ribaudo, Heather J"'

Search Results

51. Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States

52. Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV)

53. Methotrexate Inhibits T Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living With HIV

54. Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease risk

57. Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE).

62. Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV.

63. Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk

73. COVID-19 Vaccination Rates in a Global HIV Cohort

77. Cardiovascular Risk and Health Among People With HIV Eligible for Primary Prevention: Insights From the REPRIEVE Trial

78. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS clinical trials group study A5095)

79. Three- versus four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial

80. Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial

82. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

87. Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis

90. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum

91. Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE

92. Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir

93. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

96. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s

98. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease

Catalog

Books, media, physical & digital resources